Amlodipine/candesartan cilexetil - Chong Kun Dang Pharmaceutical

Drug Profile

Amlodipine/candesartan cilexetil - Chong Kun Dang Pharmaceutical

Alternative Names: Candesartan cilexetil/amlodipine - Chong Kun Dang; CKD 330

Latest Information Update: 19 Oct 2016

Price : $50

At a glance

  • Originator Chong Kun Dang
  • Class Antihypertensives; Benzimidazoles; Biphenyl compounds; Dihydropyridines; Tetrazoles
  • Mechanism of Action Angiotensin type 1 receptor antagonists; Calcium channel antagonists
  • Orphan Drug Status

    Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.

    No
  • On Fast track

    Fast track status is assigned by the US FDA so therapies with the potential to address unmet needs can move faster through development.

    No
  • New Molecular Entity No

Highest Development Phases

  • Phase III Essential hypertension

Most Recent Events

  • 01 Sep 2016 Chong Kun Dang Pharmaceutical completes a phase III trial for Hypertension (Treatment-experienced) in South Korea (PO) (NCT02586311)
  • 05 Jul 2016 Chemical structure information added
  • 01 Jan 2016 Phase-III clinical trials in Essential hypertension (Treatment-experienced) in South Korea (PO) (NCT02586311)
Restricted Access

Oops, it looks like you don’t have a valid subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • with a username/password associated to an account with a valid subscription
  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Request a trial

If you are a subscriber to this content then contact us at AsktheExpert.AdisInsight@springer.com so we can help.

Back to top